Muramatsu M, Hira T, Mitsunaga A, Sato E, Nakajima S, Kitahara Y, Eto Y, Hara H. Activation of the gut calcium-sensing receptor by peptide agonists reduces rapid elevation of plasma glucose in response to oral glucose load in rats.
glycemic control; dietary peptides; gastric emptying THE EXTRACELLULAR CALCIUM-sensing receptor (CaSR) is a member of class C G protein-coupled receptors, and it was initially identified and cloned from bovine parathyroid cells (3) . CaSR plays a crucial role in Ca 2ϩ homeostasis by regulating parathyroid hormone and calcitonin secretion (3, 12, 19) . CaSR expression has been demonstrated not only in the parathyroid glands and kidney but also in various other tissues, including the gastrointestinal tract (4) , suggesting that CaSR mediates several physiological responses in various tissues independent of Ca 2ϩ homeostasis. In addition, CaSR functions as a multimodal sensor for polyvalent cations (Ca 2ϩ and Gd 3ϩ ), aromatic L-amino acids (9, 17) , polyamines (8, 30) , basic polypeptides (protamine and poly-lysine) (13, 23) , and small peptides (24, 28, 38) .
In the gastrointestinal tract, CaSR mediates gastric acid and gastrin secretion in human gastric glands and G cells (6, 10) , and it is also involved in colonic fluid secretion (14) . Recently, our current study group, along with others, demonstrated that amino acids induce cholecystokinin (CCK) secretion via CaSR in CCK-producing enteroendocrine cells (17, 39) . Gastrin and CCK are major gut hormones that regulate gastrointestinal secretion and motility to control the digestion and absorption of nutrients. However, the role of gut CaSR on digestion/absorption or metabolism of macronutrients, including carbohydrates, remains unclear. If the activation of gut CaSR could be shown to modify postprandial glucose metabolism, it will be a promising target for the prevention or improvement of impaired glucose intolerance and obesity.
In the present study, glucose tolerance tests were performed under oral administration of several CaSR agonist peptides in conscious rats to examine whether the activation of gut CaSR affects glycemia. CaSR agonist peptides were also administered in the duodenum to determine whether they act in the small intestine. Involvement of CaSR was determined by using a CaSR antagonist. We also investigated the signaling pathways involved in the effect of CaSR agonist peptides on glycemic control by measuring the gastric emptying rate and by blocking gut hormone receptors.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (7 wk old), weighing 210 -230 g, were purchased from Japan SLC (Hamamatsu, Japan). Animals had free access to water and a semipurified diet containing 25% casein, based on AIN-93G (32) , in their individual cages. All animal experiments were performed after an acclimation period (4 -7 days) in a temperature-controlled room maintained at 23 Ϯ 2°C with a 12:12-h light-dark cycle (0800 -2000 light period). The study was approved by the Hokkaido University Animal Committee, and the animals were maintained in accordance with the Guidelines for the Care and Use of Laboratory Animals of Hokkaido University.
Experiment 1: Oral glucose tolerance test with oral administration of CaSR agonists. Rats were trained daily by orogastric administration of distilled water through a feeding tube [Safeed Feeding Tube Fr. 5 (TERUMO, Tokyo, Japan) or Atom Indwelling Feeding Tube for Infant 5Fr (Atom Medical, Tokyo, Japan)] during a 4-to 7-day acclimation period. After an overnight fasting period, rats received glucose solution (2 g/kg at a volume of 8 ml/kg body wt).
In experiments 1 and 6, CaSR agonists were gavaged with the glucose solution. The following CaSR agonists were examined: ␥Glu-Cys (␥EC; synthesized by Peptide Institute, Osaka, Japan) at 80 and 160 mg/kg, protamine (protamine sulfate from salmon, average mol wt of 5 kDa; Sigma) at 160 and 320 mg/kg, poly-lysine (poly-D-lysine hydrobromide, mol wt 30,000 -70,000; Sigma) at 50 mg/kg, and cinacalcet (CCT, chemically synthesized by methods described by Rodriguez) (33) at 20, 50, and 100 mg/kg. Casein (casein sodium salt; Wako Pure Chemical Industries, Osaka, Japan) solution was used as another polypeptide control and gavaged at 320 mg/kg (same dose as protamine).
Test solutions were prepared by using deionized water that contains no detectable calcium. The pH of the test solutions was adjusted to 7.0 for all experiments. Blood samples (35 l) were taken from the tail vein before (0 min) and after (15, 30, 60, 90 , and 120 min) administration of test solutions and collected in a tube containing heparin (final concentration of 50 IU/ml). Plasma was obtained after centrifugation and frozen at Ϫ80°C until glucose measurement. Plasma glucose concentration was measured using the Glucose CII-test kit (Wako Pure Chemical Industries).
Experiment 2: Intraperitoneal glucose tolerance test with oral administration of CaSR agonist peptides. The glucose solution was administered intraperitoneally to examine the effect of luminal peptides on glycemia independently of gastric emptying and subsequent intestinal glucose absorption. Thirty-five microliters of basal blood was collected at Ϫ15 min from the tail vein in rats fasted for 24 h just before oral administration of 8 ml/kg deionized water (as a negative control) or the CaSR agonist peptides (160 mg/kg ␥EC, 320 mg/kg protamine, 50 mg/kg poly-lysine). Glucose (1 g/kg) was injected intraperitoneally 15 min after the oral administration of the test solution (0 min), and tail vein blood was collected just before and after the glucose injection (0, 15, 30, 60, 90, and 120 min).
Experiment 3: Oral glucose tolerance test with duodenal administration of CaSR agonist peptides.
CaSR agonist peptides were administered directly in the duodenum through a duodenal catheter to examine whether the agonists exert their effect in the intestinal lumen. For implantation of a duodenal catheter, rats were fed with a reduced amount of the diet (10 g) the day before the surgical operation. A middle incision was made under pentobarbital anesthesia [40 mg/kg body wt; Nembutal injection (Dainippon Sumitomo Pharma, Osaka, Japan) or Somnopentyl injection (Kyoritsu Seiyaku, Tokyo, Japan)]. A silicone catheter (Silascon no. 00; internal diameter 0.5 mm; outer diameter 1.0 mm; Dow Corning, Kanagawa, Japan), the tip of which housed the small segment (2-3 mm) of a polyethylene tube (Hibiki Fr No. 4; Kunii, Tokyo, Japan), was inserted in the duodenum (2 cm distal to the pyloric part of the stomach) and fixed with a thread. The free end of the catheter was dorsally exteriorized, which allowed the experiment to be carried out under unanesthetized and unrestrained conditions. Rats were used for subsequent experiments after a recovery period of 3-4 days. Deionized water (as a negative control at 4 ml/kg) or test solution (40 mg/kg ␥EC, 80 mg/kg protamine, 12.5 mg/kg poly-lysine) was administered in the duodenal lumen through the duodenal catheter, just before oral glucose administration (2 g/kg, 8 ml/kg).
Experiment 4: Effects of the CaSR antagonist on CaSR agonistmodulated glycemic response under oral glucose tolerance test.
To determine the involvement of CaSR in the effect of test peptides on the glycemic response, an oral glucose tolerance test (OGTT) was performed after duodenal administration of the CaSR antagonist NPS-2143 (26, 34) . NPS-2143 was chemically synthesized following previously described methods, and its activity was determined using HEK-293 cells that were transiently transformed with the human CaSR (28) . Rats were equipped with a duodenal catheter as described above. After overnight fasting, 0.1 mg/kg NPS-2143, or its vehicle [0.0625% dimethyl sulfoxide (DMSO)], was administered in the duodenum 5 min before oral glucose Ϯ duodenal administration of CaSR agonist peptides (40 mg/kg ␥EC, 80 mg/kg protamine, or 12.5 mg/kg poly-lysine).
Experiment 5: Effects of duodenal CaSR agonists on gastric emptying. Gastric emptying was assessed by the phenol red recovery method in rats equipped with a duodenal catheter. Rats were fasted overnight before the experiment. The test solution (water as the control, 40 mg/kg ␥EC, 80 mg/kg protamine, or 12.5 mg/kg polylysine) was instilled in the duodenum through the duodenal catheter just after oral glucose administration (2 g/kg). Fifteen minutes later, phenol red solution (0.5 mg/ml at 2.5 mg/kg) containing 1.5% carboxymethyl cellulose sodium salt (Wako) was administered in the stomach. Rats were anesthetized 20 min after the administration of phenol red solution, at which point the gastric cardia and pylorus were ligated. After killing by exsanguination, gastric contents were immediately collected by flushing the interior of the stomach with 5 ml of cold saline and were stored at Ϫ20°C. After adequate dilution and alkalization with 1 N NaOH, optical absorbance was measured at 560 nm. The gastric emptying rate was calculated as the percentage of phenol red solution emptied from the stomach (36) .
Experiment 6: Effects of the serotonin and CCK receptor antagonists on the CaSR agonist peptides-modulated glycemic response under OGTT. Serotonin (5-HT) is involved in the inhibition of gastric emptying (18, 31) . OGTT was performed with duodenal CaSR agonist peptides after treatment with the 5-HT3 receptor antagonist tropisetron (3-tropanyl indole-3-carboxylate; Sigma). Rats were equipped with the duodenal catheter as described above (Experiment 3) for duodenal administration. After an overnight fast, rats received intraperitoneal administration of 1.0 mg/kg tropisetron or its vehicle (saline) 5 min before an oral administration of glucose with or without duodenal administration of agonist peptides (40 mg/kg ␥EC, 80 mg/kg protamine, 12.5 mg/kg poly-lysine).
The CCK-A receptor antagonist devazepide (DVZ; ML Laboratories, Liverpool, UK) was used to examine the involvement of another endogenous factor, CCK, in the inhibition of gastric emptying. After overnight fasting, 500 g/kg of DVZ or its vehicle (DMSO-Tween 80-saline at a ratio of 1:1:8) was intraperitoneally injected 10 min before an oral administration of glucose (2 g/kg, 8 ml/kg) with or without the CaSR agonist peptide (160 mg/kg ␥EC or 320 mg/kg protamine). To examine the efficacy of DVZ, 10 nmol/kg CCK-8 (sulfated form; Peptide Institute) was intraperitoneally injected just after oral glucose administration. Blood samples were collected from the tail vein, and plasma glucose concentrations were measured as described above.
Statistical analysis. Values are expressed as means Ϯ SE. Twoway repeated-measurement ANOVA was performed for glycemic data, and the results (effects of time, treatment, and the interaction of time and treatment) are presented in the legends for Figs. 1-7. Area under the curve (AUC, mg·dl Ϫ1 ·2 h Ϫ1 ) of plasma glucose levels during the glucose tolerance tests was calculated by the trapezoidal rule. Significant differences between mean values compared with control treatment were determined by Student's t-test for two-group comparison and by Dunnett's test for multiple comparisons (P Ͻ 0.05).
RESULTS

Oral administration of CaSR agonists attenuated elevation of plasma glucose under OGTT (experiment 1).
We first examined the effect of various CaSR agonists on the glycemic response under OGTT. The dipeptide ␥EC has been shown to be a potent agonist for CaSR both in vitro and in vivo (28) . Rats treated with 160 mg/kg of oral ␥EC showed significantly lower plasma glucose levels relative to those of control rats 15 and 30 min after oral glucose loading (Fig. 1B) . The lower dose of ␥EC (80 mg/kg) showed similar effects, although to a lesser extent (Fig. 1A) . Oral administration of CCT, a pharmacological CaSR agonist, also attenuated the glycemic response by 50 mg/kg dose, but doses at 20 and 100 mg/kg had smaller effect (Fig. 1C) . Because CCT is easily absorbed in the circulatory system (27) and acts against CaSR in the parathyroid tissue as its primary target, it is not possible to specify the site of action. Therefore, CCT was not included in the following experiments.
We further examined the effects of high-molecular-weight peptide agonists, protamine and poly-lysine (13, 23) , on the glycemic response. Plasma glucose levels in 320 mg/kg protamine-treated rats were significantly lower than those in control rats at 15 and 30 min (Fig. 1D) . In contrast, 160 mg/kg of protamine had no effect on the glycemic response. Oral administration of poly-lysine suppressed the glycemic response at 15 and 30 min when administered at a dose of 50 mg/kg ( Fig.  1E ) but had no such effect at 10 mg/kg (data not shown). Plasma glucose levels in CaSR agonist-treated rats were higher than those in control rats at 90 and 120 min (Fig. 1, A-E) . As shown in Fig. 1F , oral administration of casein, which was used as an alternative polypeptide, did not affect the glycemic response, even when administered at a dose as high as protamine (320 mg/kg).
Oral administration of CaSR agonist peptides did not attenuate plasma glucose under the intraperitoneal glucose tolerance test (experiment 2).
To examine the effects of ␥EC, protamine, and poly-lysine on glycemia without the involvement of intestinal glucose absorption, we conducted an IPGTT. Oral administration of ␥EC 15 min before intraperitoneal glucose injection did not suppress the increase in plasma glucose but rather maintained a higher glucose level than that of the control treatment ( Fig. 2A) . Rats treated with protamine or poly-lysine had slightly lower glucose levels than control rats at 15 and 30 min, although these differences were not statistically significant (Fig. 2B) .
Duodenal administration of ␥EC or protamine, but not free Glu and Cys, lowered the glycemic response under OGTT (experiment 3). CaSR agonist peptides were directly administered in the duodenal lumen under OGTT to determine whether the agonists act in the small intestine. Even at a quarter of the oral administration dose, both duodenal ␥EC (40 mg/kg) and protamine (80 mg/kg) significantly reduced the elevation of plasma glucose at 15 and 30 min compared with control treatment (Fig. 3A) . A mixture of glutamic acid and cysteine (0.16 mmol/kg each), components of the ␥EC peptide, did not affect the glycemic response in contrast to the same dose (40 mg/kg ϭ 0.16 mmol/kg) of ␥EC (Fig.  3B ). This result indicates that suppression of the glycemic response was not due to free amino acids or the osmotic effect of the test solutions.
CaSR mediates the glucose-lowering effect of ␥EC, protamine, and poly-lysine (experiment 4). The involvement of CaSR on the effect of test peptides was examined by duodenal administration of the CaSR antagonist NPS-2143 (26, 34) . Significant reduction of plasma glucose by duodenal ␥EC (␥EC/vehicle group) at 15 min was disappeared by duodenal pretreatment with NPS-2143 (␥EC/NPS group). Reduction by ␥EC at 30 min was also weakened by NPS-2143 treatment (Fig. 4A ). Significant reduction of plasma glucose by protamine was cancelled at 30 min by duodenal NPS-2143 treatment, and the antagonist shifted the glycemic curve of protamine-treated rats upward (Fig. 4B) . Glucose levels of polylysine-treated rats were significantly lower than those of control/vehicle-treated rats at 15 and 30 min, and the effect was Glucose (mg/dl) weakened by NPS-2143 treatment (Fig. 4C) . NPS-2143 itself did not enhance the glycemic response under OGTT (Fig. 4D) .
Effect on gastric emptying (experiment 5).
The gastric emptying rate is one of the critical factors related to postprandial glycemia. Because the results of experiments 1-3 raised the possibility that delayed glucose absorption, rather than an insulin-dependent mechanism, was involved in the glucoselowering effect of CaSR agonist peptides, we measured the gastric emptying rate after duodenal administration of these peptides. The gastric emptying rates of the phenol red solution were lower in rats treated with ␥EC, protamine (Fig. 5A) , and poly-lysine (Fig. 5B ) than those in control rats. Test solution containing CaSR agonists was administered in the duodenum 5 min after NPS-2143 or vehicle administration, and then glucose solution was gavaged (2 g/kg) in every group (0 min). A: control (water) at 4 ml/kg after vehicle administration (▫, n ϭ 9), ␥EC at 40 mg/kg after vehicle administration (, n ϭ 9), and ␥EC at 40 mg/kg after NPS administration ({, n ϭ 8). B: control (water) at 4 ml/kg after vehicle administration (▫, n ϭ 13), protamine (Prot) at 80 mg/kg after vehicle administration (OE, n ϭ 12), and Prot at 80 mg/kg after NPS administration ({, n ϭ 13). C: control (water) at 4 ml/kg after vehicle administration (▫, n ϭ 7), poly-lysine at 12.5 mg/kg after vehicle administration (, n ϭ 7), and poly-lysine at 12.5 mg/kg after NPS administration ({, n ϭ 6). D: control at 4 ml/kg after vehicle (▫, n ϭ 6) or NPS administration ({, n ϭ 10). Tables  in each panel Gastric emptying rate (%) Fig. 5 . Gastric emptying rate after duodenal administration of CaSR agonist peptides. Test solution containing CaSR agonists was administered in the duodenum followed by oral glucose administration (2 g/kg). A: control (water) at 4 ml/kg (n ϭ 7), ␥EC at 40 mg/kg (n ϭ 8), and protamine at 80 mg/kg (n ϭ 7). B: control (water) at 4 ml/kg (n ϭ 10), and poly-lysine at 12.5 mg/kg (n ϭ 11 
Involvement of 5-HT 3 /CCK receptors in the glucoselowering effect of the peptides (experiments 6 and 7).
Consistent with the results of experiments described above, duodenal administration of ␥EC, protamine, and poly-lysine lowered the glycemic response under OGTT (Fig. 6, A-C) . Intraperitoneal injection of tropisetron (a 5-HT 3 receptor antagonist) almost completely attenuated the effect of protamine (Fig. 6B) and partially attenuated those of ␥EC (Fig.  6A ) and poly-lysine (Fig. 6C) . Injection of tropisetron in control rats slightly reduced, but did not enhance, the glycemic response (Fig. 6A) . Intraperitoneal DVZ (a CCK-A receptor antagonist) injection did not influence the glucose-lowering effects of oral ␥EC and protamine (Fig. 6,  D and E B: control (water) at 4 ml/kg after vehicle (▫, n ϭ 7), protamine [at 80 mg/kg after vehicle (OE), n ϭ 6], or Tropi ({, n ϭ 7) administration. C: control (water) at 4 ml/kg after vehicle (▫, n ϭ 10) and poly-lysine (Poly-Lys) at 12.5 mg/kg after vehicle (, n ϭ 9) or Tropi ({, n ϭ 8) administration. D and E: devazepide (DVZ, 500 g/kg) or its vehicle was injected ip 10 min before an oral administration of glucose solution (2 g/kg, 8 ml/kg) containing CaSR agonists. D: control (water) at 8 ml/kg after vehicle (▫, n ϭ 7) or DVZ (o, n ϭ 7) administration and ␥EC at 160 mg/kg after vehicle (, n ϭ 7) or DVZ ({, n ϭ 7) administration. E: control (water) at 8 ml/ kg after vehicle (▫, n ϭ 7) or DVZ (o, n ϭ 7) administration and protamine at 320 mg/kg after vehicle (OE, n ϭ 6) or DVZ ({, n ϭ 6) administration. F: devazepide (500 g/kg) or its vehicle was injected ip 10 min before an oral administration of glucose (2 g/kg, 8 ml/ kg) and ip injection of CCK (10 nmol/kg); n ϭ 8 in each treatment. Tables in each panel sufficient to completely block the glucose-lowering effect of exogenous CCK (Fig. 6E) .
DISCUSSION
In the present study, we found that CaSR agonist peptides in the intestinal lumen reduce the glycemic response under OGTT in rats. The glucose-lowering effect was accompanied with suppression of gastric emptying and was mediated by 5-HT 3 receptor activation (Fig. 7) . These results suggest that activation of the gut CaSR can be a novel target for the attenuation of postprandial hyperglycemia.
Postprandial glycemia is regulated and affected by several factors. Insulin lowers glycemia by inducing glucose uptake in peripheral tissues. Insulin secretion is stimulated not only by plasma glucose elevation but also by incretin hormones such as glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (1) . The rate of carbohydrate digestion/absorption in the small intestine also affects glycemia. ␣-Glucosidase inhibitors attenuate postprandial glycemia and insulin secretion through delayed digestion of carbohydrates (15, 16) . Inhibition of gastric emptying also contributes to the prevention of postprandial hyperglycemia by reducing carbohydrate/glucose delivery in the small intestine. Gastric emptying is delayed by luminal glucose or fatty acids in the small intestine, which is mediated by the release of gastrointestinal hormones, including CCK, 5-HT, and GLP-1 (2, 20, 25, 31) .
We initially found that oral administration of ␥EC, protamine, and poly-lysine effectively attenuated the glycemic response under OGTT in conscious rats (Fig. 1) . The glycemic response was also attenuated by a pharmacological CaSR agonist, CCT (Fig. 1C) , at a higher dose than those used in pharmacodynamics studies (27) . These agonists exhibited a glucose-lowering effect immediately (15 min) after the oral administration. Additionally, the peak of glycemic responses was delayed in ␥EC-, protamine-, and poly-lysine-treated rats compared with that of the control treatment, suggesting slower glucose absorption. Because high-molecular-weight peptides such as protamine (average mol wt 6,250) and poly-lysine (average mol wt 50,000) are not absorbed through the intestinal epithelium in their intact forms, it is likely that these peptides or its fragments act on the apical site of the gastrointestinal epithelium. Oral administration of CaCl 2 solution (ϳ10 mM) did not affect glycemic responses in our experimental conditions (data not shown), suggesting specific properties of peptide are critical for acting in the gastrointestinal lumen.
In contrast to OGTT results, these peptides were not effective in attenuating plasma glucose under the IPGTT (Fig. 2) . Because insulin is the main factor involved in reducing glycemia under the IPGTT, this result indicates that CaSR agonist peptides exert glucose-lowering effects independently of insulin secretion. Plasma insulin response was lower in protamine (320 mg/kg)-gavaged rats compared control rats under OGTT (data not shown), supporting the notion.
Duodenal administration of ␥EC, protamine, and polylysine, at a quarter of the dose of oral administration, reduced the glycemic response under OGTT (Fig. 3 ) in a similar manner as was observed with oral administration of these peptides (Fig. 1) . This indicates that CaSR agonist peptides act in the small intestine and suggests that the peptides partially delivered in the small intestine from the stomach exerted the glucose-lowing effects in the oral administration experiment. Although initial glycemic responses (15-30 min) were clearly reduced by CaSR agonist peptides, AUC of glycemia were not always decreased (except Fig. 3 ) by the treatment because of elevation of glycemia in a later period (60 -120 min). CaSR agonist peptides may contribute to preventing from postprandial glucose spike rather than reducing total amount of glucose absorption.
Pretreatment with the specific CaSR antagonist NPS-2143 partially reversed the glucose-lowering effect of CaSR agonist peptides (Fig. 4) . Incomplete reversal by the antagonist treatment may have been the result of the insufficient inhibition of CaSR under the experimental conditions or the involvement of additional mechanisms. Possibly, peptide fragments or free amino acids derived from the agonist peptides or the intact peptides affected an unknown pathway to reduce glucose uptake in the intestine. Nonetheless, the data demonstrate that CaSR is at least partially responsible for the glucose-lowering effect of luminal ␥EC, protamine, and poly-lysine.
The delayed peak of the glycemic response under OGTT (Figs. 1, 3, and 4) , and the lack of the effect under the IPGTT (Fig. 2) , raised the possibility that the CaSR agonist peptides inhibit gastric emptying. This was confirmed in experiment 5, which showed that gastric emptying rates in the peptide-treated rats were lower than those of control rats (Fig. 5) . This effect likely contributes to lowering the glycemic response. Gastric emptying is inhibited by gut hormones such as CCK, GLP-1, and 5-HT. We, along with others, recently demonstrated CaSR-mediated CCK secretion in CCK-producing cells (17, 21, 39) . However, treatment with the CCK-A receptor antagonist (DVZ) did not influence the glucose-lowering effect of CaSR agonist peptides (Fig. 6, D and E) , indicating that endogenous CCK is not involved. In contrast, the results of experiment 6 using tropisetron (Fig. 6, A-C agonists stimulate 5-HT secretion via CaSR activation, which leads to the inhibition of gastric emptying and the subsequent delay of glucose delivery in the small intestine. However, incomplete cancellation by tropisetron and NPS-2143 suggests the involvement of another pathway. In addition to the pathway described above, peptides and/or those digestive products possibly affected other peptide receptors to inhibit gastric emptying and/or intestinal glucose absorption; such mechanisms need to be elucidated in the future. It is possible that CaSR is expressed and functions in 5-HT-producing enterochromaffin (EC) cells. This hypothesis appears to be supported by some previous studies. CaSR is detected in several enteroeodocrine cells, such as chromogranin A-positive cells (35) . Chromogranin A is a major marker molecule for enteroendocrine cells, including EC cells (5, 7) . In gastric G cells, CaSR regulates both the secretion of gastrin in response to various luminal nutrients and the maintenance of G cell numbers (11) . In CCK-producing cells, CaSR mediates amino acid-induced CCK secretion (17, 21, 39) . With regard to 5-HT-producing cells, a previous study has reported that CaSR mediates extracellular Ca 2ϩ -induced 5-HT secretion in 5-HT-producing parafollicular cells (22) . However, further study is needed to investigate the expression and role of CaSR in EC cells.
Control of postprandial glycemia is a promising target for the prevention and improvement of impaired glucose tolerance in obesity and diabetes. Prevention of postprandial hyperglycemia currently involves slowing carbohydrate digestion by dietary fibers (indigestible dextrin, guar gum, etc.) or ␣-glucosidase inhibitors (15, 16, 29, 37) . Delayed glucose absorption by the peptides demonstrated in the present study could also contribute to preventing the immediate occurance of hyperglycemia in response to meal ingestion (glucose spike). The results of the present study provide a novel approach for the improvement of glycemic control, that is, stimulating gut CaSR by oral agonists prevents postprandial hyperglycemia.
In conclusion, the activation of gut CaSR by peptide agonists (␥EC, protamine, and poly-lysine) improved glucose tolerance in rats. The delayed gastric emptying rate, which is mediated by a 5-HT signal, appears to have a role in the glucose-lowering effect of the peptides. Our results indicate the possible involvement of CaSR in nutrient sensing, and also suggest that gut CaSR could be a potential target for the improvement of glucose tolerance.
GRANTS
This work was supported, in part, by JSPS KAKENHI Grant No. 21780118.
DISCLOSURES
No potential conflicts of interest relevant to this article were reported. 
AUTHOR CONTRIBUTIONS
